# Bolt Biotherapeutics

Source: https://onco.cc/companies/bolt-biotherapeutics/  
OnCo record `bolt-biotherapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Bolt Biotherapeutics builds antibodies that carry an immune-stimulating payload into tumours so the body's own myeloid cells attack the cancer; BDC-4182 aims this at Claudin 18.2.

## Summary

Bolt Biotherapeutics develops Boltbody immune-stimulating antibody conjugates (ISACs), which link a tumour-targeting antibody to a Toll-like receptor agonist that activates myeloid cells inside the tumour. Its first programme, the HER2-directed trastuzumab imbotolimod (BDC-1001), was followed by BDC-3042, a Dectin-2 agonist antibody, and BDC-4182, a Claudin 18.2 ISAC that entered the clinic for gastric and pancreatic cancers.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Bolt Bio; NASDAQ:BOLT
- Tags: drug-maker
- HQ: Redwood City, California
- Type: biotech
- Website: https://www.boltbio.com/
- Ticker: NASDAQ:BOLT

## Sources

- Official website: https://www.boltbio.com/

## Connected records

- drugs: [BDC-4182](https://onco.cc/drugs/bdc-4182/)

---
JSON: https://onco.cc/api/v1/entities/bolt-biotherapeutics.json